Get 25% discount on our yearly plans! Subscribe now

FLXN by TradingView
Key Metrics
Market Cap
Total Shares Outstanding
Book Value
PE Ratio
PS Ratio
PB Ratio
Forward PE Ratio
ROIC
Return on Aseets
Return on Equity
Dividend
Dividend Yield
Balancesheet Metrics
Total Assets
Total Liability
Assets-to-Libability Ratio
Total Current Assets
Total Current Liability
Current Ratio
Quick Ratio
Debt to Equity Ratio
Income Statement Metrics
Net Income
EPS
EBITA
Gross Profit
Gross Profit Margin
Operating Margin
Net Profit Margin
Price Metrics
5 Days MA
10 Days MA
20 Days MA
50 Days MA
200 Days MA
52 Weeks High
52 Weeks low
All Time High
RSI
MACD
Share Stats
Shares Float
Shares Short
% Short
% Insider
% Institutions
News

Profile

Flexion Therapeutics Inc (FLXN)

Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts. As of November 19, 2021, Flexion Therapeutics, Inc. operates as a subsidiary of Pacira BioSciences, Inc..

Exchange: NASDAQ

IPO Date: 2/12/2014

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 257

Address: 10 Mall Road, Burlington, MA, United States, 01803

http://www.flexiontherapeutics.com

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;Totals
Totals-
&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;Totals
Totals-
&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;Totals
Totals-
&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;Totals
Totals-
&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;Totals
Totals-
&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;Totals
Totals-